文献速递糖尿病

成人1型糖尿病动态血糖监测与自我血糖监测的成本效果:DIAMOND随机试验

Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
PubMed 文献 · Diabetes Care · 2018-04-12

基于DIAMOND随机试验,纳入158例HbA1c≥7.5%的1型糖尿病成人患者,按2:1随机分为动态血糖监测(CGM)组与对照组。6个月内CGM组QALY与对照组相似,但HbA1c、非严重低血糖事件及试纸使用减少;终生分析中CGM增加0.54个QALY,ICER为每QALY 98,108美元,传感器使用延长至10天时ICER降至33,459美元。作者认为在支付意愿阈值每QALY 100,000美元下CGM具有成本效果。

要点

  • 6个月内CGM组与对照组QALY相似(0.462 vs 0.455年,P=0.61)。
  • CGM组HbA1c差值差异0.60%,非严重低血糖日发生率差值差异0.07,试纸日使用差值差异0.55。
  • 终生分析ICER为每QALY 98,108美元,传感器使用7天延长至10天时降至33,459美元。

核心结论

  • 对于使用多次胰岛素注射且血糖控制仍不理想的1型糖尿病成人,在每QALY 100,000美元支付意愿阈值下CGM具有成本效果,并改善血糖控制、减少非严重低血糖。

研究设计与样本

  • DIAMOND随机试验纳入158例HbA1c≥7.5%的1型糖尿病成人,按2:1随机分为CGM组与对照组,在基线及6个月时进行调查,并进行试验内及终生成本效果分析;使用改良Sheffield 1型糖尿病政策模型模拟并发症。

主要发现

  • 6个月试验内,CGM组与对照组QALY相似(0.462±0.05 vs 0.455±0.06年,P=0.61)。
  • 6个月总成本CGM组为11,032美元,对照组为7,236美元。
  • 与对照组相比,CGM组HbA1c差值差异为0.60±0.74%(P<0.01),非严重低血糖日发生率差值差异为0.07(P=0.013),试纸日使用差值差异为0.55±1.5(P=0.04)。
  • 终生分析中,CGM预计降低1型糖尿病并发症风险并增加0.54个QALY;总体人群ICER为每QALY 98,108美元。
  • 在真实世界场景中将传感器使用从7天延长至10天,ICER降至每QALY 33,459美元。

关键数值与推荐

  • 6个月试验内QALY:CGM组0.462±0.05年 vs 对照组0.455±0.06年,P=0.61。
  • 6个月总成本:CGM组11,032美元 vs 对照组7,236美元。
  • HbA1c差值差异0.60±0.74%(P<0.01),非严重低血糖日发生率差值差异0.07(P=0.013),试纸日使用差值差异0.55±1.5(P=0.04)。
  • 终生分析:CGM增加0.54个QALY,总体人群ICER为每QALY 98,108美元;传感器使用7天延长至10天时ICER为每QALY 33,459美元。

临床怎么用

  • 对于使用多次胰岛素注射且血糖控制仍不理想的1型糖尿病成人,在每QALY 100,000美元支付意愿阈值下CGM具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated the societal cost-effectiveness of continuous glucose monitoring (CGM) in patients with type 1 diabetes (T1D) using multiple insulin injections. RESEARCH DESIGN AND METHODS: In the Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes (DIAMOND) trial, 158 patients with T1D and HbA1c ≥7.5% were randomized in a 2:1 ratio to CGM or control. Participants were surveyed at baseline and 6 months. Within-trial and lifetime cost-effectiveness analyses were conducted. A modified Sheffield T1D policy model was used to simulate T1D complications. The main outcome was cost per quality-adjusted life-year (QALY) gained. RESULTS: Within the 6-month trial, the CGM group had similar QALYs to the control group (0.462 ± 0.05 vs. 0.455 ± 0.06 years, P = 0.61). The total 6-month costs were $11,032 (CGM) vs. $7,236 (control). The CGM group experienced reductions in HbA1c (0.60 ± 0.74% difference in difference [DiD]), P < 0.01), the daily rate of nonsevere hypoglycemia events (0.07 DiD, P = 0.013), and daily test strip use (0.55 ± 1.5 DiD, P = 0.04) compared with the control group. In the lifetime analysis, CGM was projected to reduce the risk of T1D complications and increase QALYs by 0.54. The incremental cost-effectiveness ratio (ICER) was $98,108 per QALY for the overall population. By extending sensor use from 7 to 10 days in a real-world scenario, the ICER was reduced to $33,459 per QALY. CONCLUSIONS: For adults with T1D using multiple insulin injections and still experiencing suboptimal glycemic control, CGM is cost-effective at the willingness-to-pay threshold of $100,000 per QALY, with improved glucose control and reductions in nonsevere hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wan W, Skandari MR, Minc A, et al. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care. 2018. PMID: 29650803. doi:10.2337/dc17-1821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。